Platform Validation & Development

About MabSwitch

MabSwitch is a preclinical-stage biotech pioneering a novel class of 'switchable' antibodies. Its core UNASMA™ technology inserts an allosteric switch module into antibodies, allowing their binding affinity to be turned ON or OFF via small molecules under physiological conditions. This platform has broad potential applications, including improving the safety profile of next-generation immunotherapies (like CAR-T cells and bispecifics) and creating reusable diagnostic and purification reagents. The company is currently in the technology development and validation phase, seeking to translate its platform into therapeutic and industrial partnerships.

Therapeutic Areas